Chemotherapy-related cardiomyopathy: All that glitters is not gold

Congestive Heart Failure

Volumn 9, Issue 1, 2003, Pages 47-49

  Morshedi Meibodi, Ali ^a   Uber, Patricia A ^a   Mehra, Mandeep R ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARVEDILOL; CYCLOPHOSPHAMIDE; PREDNISONE; RAMIPRIL;

ADULT; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CASE REPORT; COMBINATION CHEMOTHERAPY; DIAGNOSTIC ACCURACY; HEART FAILURE; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MORBIDITY; PATHOGENESIS; POLYMYOSITIS; SCLERODERMA; CHEMICALLY INDUCED DISORDER; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DRUG COMBINATION; MIDDLE AGED; SYSTEMIC SCLEROSIS;

CARDIOMYOPATHY, DILATED; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 0037266725     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-5299.2002.01902.x     Document Type: Article

References (13)

1. Askari AD. Inflammatory disorders of muscle. Cardiac abnormalities. Clin Rheum Dis. 1984;10:131-149.
2. Bristow MR, Billingham ME, Mason JW, et al. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978;62:873-879.
3. Moreb JS, Oblon DJ. Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer. 1992;70:2637-2641.
4. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47-58.
5. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95:1592-1600.
6. DelaFlor-Weiss E, Uziely B, Muggia FM. Protracted drug infusions in cancer treatment: an appraisal of 5-fluorouracil, doxorubicin, and platinums. Ann Oncol. 1993;4(9):723-733.
7. Blajman C, Balbiani L, Block J, et al. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. Cancer. 1999;85:1091-1097.
8. Zambetti M, Moliterni A, Materazzo C, et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol. 2001;19:37-43.
9. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22:263-302.
10. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738-1743.
11. Wexler LH. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane. Semin Oncol. 1998;25(4 suppl 10):86-92.
12. Valero V, Buzdar AU, Theriault RL, et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999;17:1425-1434.
13. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133-139.